I haven't assumed anything and I am certainly not ignorant...neither do I intend to sound condescending and am certainly not advising anyone on investing...
You made an excellent point in your first post about FDA comments
and uncertainty...based on the spin from MB's and tweets you are quite right and Monday morning is going to be very interesting...
If not having an answer to your question is ignoring it I am sorry, that was not my intent...I don't have the answers but did attempt to provide some feedback on where those answers might be found to each individual investor's satisfaction, because I can't see where anyone would have a definitive answer...bullish or bearish...
I am not an expert on the IND process, but I do think the primary concern is safety and any negative "comments" would arise from that issue being found in the data packet filed with the IND. I find it hard to believe there is a safety issue when there was a 2 year safety study done at Mclean's Hospital early on, several peer-reviewed pre-clinical studies, and "clinical trial" type data on over 800 human patients and now over 90 million tablets circulated with nary a problem.
So what could the "comments" be? Good? Guidance?
I don't know but after listening to Dr. Chapman again...he seemed rather confident, competent and excited...
Happy trials...
AI
